<DOC>
	<DOC>NCT01477528</DOC>
	<brief_summary>The purpose of this observational study is to obtain multi-center data on HeartMate II (HMII) patients managed with reduced anticoagulation or anti-platelet regimes, and the incidence of thrombotic and bleeding adverse events associated with these regimes.</brief_summary>
	<brief_title>Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)</brief_title>
	<detailed_description />
	<criteria>HeartMate II Left Ventricular Assist Device (LVAD) patient Patient has signed an informed consent for data collection. Patient was discharged, or is being discharged, from the hospital after their initial LVAD implant surgery. Patient: at time of enrolling in study, is currently on, with the intention of being maintained on reduced antithrombotic therapy (RT) for chronic longterm management. OR On or after January 1, 2011 patient was being maintained on, or had been initiated with the intention of being maintained on, reduced antithrombotic therapy (RT) for chronic longterm management; but where RT was subsequently discontinued due to an adverse event or transplant, explant, or death. Patients under acute management of antithrombotic agents before a final decision on long term antithrombotic strategy. Patients requiring a legal representative to sign consent form, rather than themselves. Patient is being managed on other antithrombotic agents</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HeartMate II</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Thoratec Corporation</keyword>
</DOC>